logo
The butterfly effect: A misaligned experiment accidentally unfolds quantum wings

The butterfly effect: A misaligned experiment accidentally unfolds quantum wings

Yahoo23-03-2025
In a remarkable scientific breakthrough, researchers at Princeton University have observed a fractal energy pattern in quantum materials that had only been predicted on paper for nearly fifty years.
Known as Hofstadter's butterfly, this intricate design emerges from the behavior of electrons in certain conditions.
Originally theorized in 1976 by physicist Douglas Hofstadter, the pattern had never been directly observed in an actual material — until now.
The discovery came as a surprising outcome of research focused on superconductivity, where a small experimental mistake opened the door to this long-sought-after observation.
The discovery was made possible by recent developments in materials science, where scientists are able to stack and twist extremely thin layers of carbon atoms — known as graphene — into specific structures.
This twisting creates moiré patterns, a kind of interference design similar to overlapping fabrics.
'These moiré crystals provided an ideal setting to observe Hofstadter's spectrum when subjecting electrons moving in them to a magnetic field. These materials have been extensively studied, but up to now the self-similarity of the energy spectrum of these electrons had remained out of reach,' explained Ali Yazdani, James S. McDonnell Distinguished University Professor at Princeton.
Interestingly, the discovery happened by accident.
The research team, led by Yazdani, was originally studying superconductivity in twisted bilayer graphene.
'Our discovery was basically an accident,' admitted Andrew Nuckolls, one of the researchers. 'We didn't set out to find this.'
Dillon Wong, postdoctoral research associate and co-lead author of the paper, elaborated, 'We were aiming to study superconductivity, but we undershot the magic angle when we were making these samples.'
This misstep produced a longer moiré periodicity than planned — but exactly the right conditions for observing the fractal spectrum.
capable of imaging atoms by measuring the tiny quantum currents that flow between the microscope tip and the surface.
While using the STM, the team noticed unusual behavior in electron energy levels.
'The STM is a direct energy probe, which helps us relate back to Hofstadter's original calculations, which were calculations of energy levels,' said Myungchul Oh, a postdoctoral research associate and co-lead author.
Electrical resistance measurements in past studies had hinted at the butterfly pattern, but the STM allowed for direct visualization.
'Sometimes nature is kind to you,' said Nuckolls. 'Sometimes nature gives you extraordinary things to look at if you stop to observe it.'
The team's work also shed light on how electrons interact with each other in these complex materials.
While Hofstadter's original calculations did not account for electron interactions, this experiment showed that including these effects made the models more accurate.
'The Hofstadter regime is a rich and vibrant spectrum of topological states, and I think being able to image these states could be a very powerful way to understand their quantum properties,' said Michael Scheer, a graduate student and co-lead author.
Though immediate applications are unclear, this accidental discovery opens exciting new possibilities for understanding quantum materials.
The study was published in the journal Nature.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'I'd bet my house' on treatment for Alzheimer's, says Nobel prize winner
'I'd bet my house' on treatment for Alzheimer's, says Nobel prize winner

Yahoo

time31-07-2025

  • Yahoo

'I'd bet my house' on treatment for Alzheimer's, says Nobel prize winner

A Nobel Prize-winning Scottish chemist has told the BBC he thinks drugs to treat Alzheimer's disease will be available within five years. Princeton University's Prof David MacMillan, who is originally from North Lanarkshire, said "phenomenal things" are happening within medical research into neurological diseases. "I would bet my house that within five years that we have marketed drugs for Alzheimer's," Prof MacMillan told the BBC's Scotcast podcast. "My father died of vascular dementia and my aunt had dementia. I think that's such a horrible way to go." The Scottish scientist was awarded the 2021 Nobel Prize in Chemistry alongside Prof Benjamin List after developing a new way of building molecules. Their work has led to developments in drugs for Alzheimer's, cancer and heart disease. Prof MacMillan, 57, said the award had made a massive impact on his life "On a Tuesday morning, I was a chemist that nobody, including half my pals, had been interested in talking to," he said. "Then on the Wednesday, I was talking to like the New York Times and the Wall Street Journal. "It was crazy - and I thought it would slow down but it just keeps on going." Prof MacMillan was awarded a half share of 10 million Norwegian krona (£842,611). He used it to set up The May and Billy MacMillan Foundation, named after his parents, where he funds Scottish students, providing educational opportunities to underprivileged young people. He said education and learning was always good and gaining more experience was incredibly important. It is something he knows about from his own life. He grew up in New Stevenston, near Bellshill, and gained his undergraduate degree in chemistry at the University of Glasgow before moving to the US for postgraduate studies. "I realised that education is your passport to the world," he said. After studying in California in the early 1990s, he moved to Harvard and the University of California at Berkeley before becoming a professor at Princeton in 2006. He said working in the US had been great because its "research is the infrastructure that drives the health of the world". The possibilities of the people he was able to collaborate with had been "mind-boggling", he said. However, recent developments in US universities are causing concern, he said. President Donald Trump and his Vice-President JD Vance have long railed against higher education institutions and they have been putting pressure on them over funding. For the first time in 25 years, Prof Macmillan's research group at Princeton has received no funding for the first seven months of the year from the US government. He said: "Americans still care about the Nobel Prize. "If that could happen to somebody like me, it could happen to anybody." The scientist said that academics were now the resistance as they try to deal with the politics of the current US administration "without selling their soul". Prof MacMillan said the cuts were "quite sinister" because it seemed like a way to control universities and the narrative by deciding who they can hire. Higher education has become a hub for progressive thinking, which in his opinion, he said the Republicans don't like. "What they care the most about is retaining power," he said. Despite the pressure in the US, Prof MacMillan is not planning a return to Scotland just yet but he does regularly come back to see family - and some newfound friends. He told the podcast he had become good friends with a Scottish legend who phoned to congratulate him after he won the Nobel prize. Most people would ignore a call that said 'No Caller ID' but he answered to find Sir Alex Ferguson on the other end of the line. The professor, who was himself knighted in 2022, said he thought one of his friends had been joking with him by pretending to be Sir Alex. But he recognised that the voice sounded too similar to the former Manchester United football manager. The two spoke about their common ground of growing up in Glasgow and the pair are now good friends who will be watching Manchester United play Chelsea together later in the year. Prof MacMillan not only sits next to Sir Alex at football games, the two will now feature together in the National Portrait Gallery of Scotland as the Scots chemist has had his portrait unveiled. The Scots scientist said he was "blown away by it". The painting by Christabel Blackburn depicts the chemist sitting in his office with a white lab coat in the corner. Prof MacMillan said it was actually a lab coat that he was "quite proud of" because it had been presented to him from his old school Bellshill Academy - which now sits in his office in Princeton University. 'Being Scottish helped me win Nobel Prize' Captain Kirk calls me for science lessons Nobel winner gives prize money to Scots students

Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Yahoo

time22-07-2025

  • Yahoo

Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Updated efficacy data will be presented from the REZILIENT1 trial of zipalertinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who were previously treated with amivantamab Preliminary findings to be shared from the cohort of patients with uncommon non-ex20ins EGFR mutations enrolled in the REZILIENT2 trial of zipalertinib PRINCETON, N.J. and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced the presentation of new data from zipalertinib REZILIENT1 and REZILIENT2 trials at the International Association of the Study of Lung Cancer's (IASLC) 2025 World Conference on Lung Cancer (WCLC), to be held September 6-9, 2025, in Barcelona, Spain. The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 trial, focusing on patients with EGFR ex20ins NSCLC previously treated with amivantamab, as well as the preliminary efficacy and safety results from the Phase 2 parallel cohort REZILIENT2 trial in patients with advanced or metastatic NSCLC harboring uncommon non-ex20ins EGFR mutations. "Previously, zipalertinib has demonstrated clinical activity against ex20ins and preclinical activity against uncommon, non-ex20ins EGFR-mutant NSCLC," said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. "We look forward to sharing updated data from the REZILIENT1 and REZILIENT2 trials at the upcoming 2025 World Conference on Lung Cancer, suggesting the potential for zipalertinib to make a meaningful difference in the lives of patients with certain types of NSCLC." "Despite advances in the treatment landscape, there remains significant unmet need for NSCLC patients with EGFR exon 20 insertion mutations and for those with uncommon non-ex20ins EGFR mutations," said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. "Taken together, the updated results from REZILIENT1 and new data from the REZILIENT2 study highlight the potential of zipalertinib to play an important role in the evolving treatment landscape for patients with NSCLC harboring less common EGFR mutations." Session titles and information for the two abstracts are listed below. Full abstract details will be available via the conference website at 1 p.m. EDT August 13, 2025. Title: Zipalertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab Session Name: MA08 - Common and Uncommon EGFR Mutations, New Treatments in the HorizonSession Type: Mini Oral PresentationSession Date: Tuesday, September 9, 2025Session Time: 11:30 a.m. – 12:45 p.m. CESTPresenter: Zofia Piotrowska, MD Title: Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR MutationsSession Name: MA08 - Common and Uncommon EGFR Mutations, New Treatments in the Horizon Session Type: Mini Oral PresentationSession Date: Tuesday, September 9, 2025Session Time: 11:30 a.m. – 12:45 p.m. CESTPresenter: Hibiki Udagawa, MD, PhD About ZipalertinibZipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib has received Breakthrough Therapy Designation from the FDA. Zipalertinib is investigational and has not been approved by any health authority. Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S. About Taiho Oncology, mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada. For more information, visit and follow us on LinkedIn and X. Taiho Oncology and the Taiho Oncology logo are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries. About Cullinan TherapeuticsCullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan's portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at and follow us on LinkedIn and X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company's beliefs and expectations regarding our plans regarding future data presentations, the clinical development and regulatory filing plan and timeline of zipalertinib, the safety and efficacy profile of zipalertinib and its potential to address unmet medical need, and other statements that are not historical facts. The words "believe," "continue," "could," "estimate," "expect," "intends," "may," "plan," "potential," "project," "pursue," "will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any NDA or other regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Contacts Taiho OncologyLeigh Labrie+1 609.664.9878 LLabrie@ Cullinan TherapeuticsInvestorsNick Smith+1 401.241.3516nsmith@ Media Rose Weldon +1 215.801.7644 rweldon@ View original content to download multimedia: SOURCE Taiho Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Private conversations with Albert Einstein published as book
Private conversations with Albert Einstein published as book

Yahoo

time21-07-2025

  • Yahoo

Private conversations with Albert Einstein published as book

Records from Albert Einstein's final years are being published as a book around 20 years after their discovery, as transcripts of telephone conversations the physicist had between 1953 and 1955, publisher Heyne Verlag announced on Monday. The records by Johanna Fantova, considered to be Einstein's last close female friend, describe events from the last year and a half before the scientist's death at the age of 76. Einstein (1879-1955), who fled Nazi Germany for the United States in 1933, reportedly shared his daily experiences in US exile with Fantova over the phone. Fantova, who first met Einstein in Germany but also moved to the US, transcribed his statements with his consent, the publisher said. The 62-page typescript in German was discovered by chance in 2004 at the Firestone Library of Princeton University, where Fantova once worked as a curator. The materials lay unprocessed in the archive for a long time. The diary entries are now set to be published for the first time in an annotated edition with additional findings on September 24. The title of the book by Peter von Becker is: "I am a Magnet for All the Maniacs. The Einstein Transcripts – His Life, His Last Love, His Legacy." In the diary, Einstein - who revolutionized physics with his Theory of Relativity - shares his thoughts on politics, science, everyday life and love. For instance, he criticized the arms race of the superpowers and the rearmament of Germany, and commented on the conflict between Israelis and Palestinians, according to the publisher. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store